Page last updated: 2024-11-13

gw280264x

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GW280264X: capable of blocking tumor necrosis factor-alpha-converting enzyme (TACE) and the closely related disintegrin-like metalloproteinase 10 (ADAM10) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91885425
SCHEMBL ID22889513
MeSH IDM0474450

Synonyms (15)

Synonym
gw280264x
866924-39-2
benzyl((s)-5-((2r,3s)-3-(n-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate
MS-30361
benzyl ((s)-5-((2r,3s)-3-(n-hydroxyformamido)-2-isobutylhexanamido)-6-oxo-6-(thiazol-2-ylamino)hexyl)carbamate ,
benzyl n-[(5s)-5-[[(2r,3s)-3-[formyl(hydroxy)amino]-2-(2-methylpropyl)hexanoyl]amino]-6-oxo-6-(1,3-thiazol-2-ylamino)hexyl]carbamate
SCHEMBL22889513
HY-115670
EX-A4730
(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]- 6-oxo-6-(2-thiazolylamino)hexyl]-carbamate
benzyl n-[(5s)-5-[[(2r,3s)-3-
CS-0104321
AKOS040759593
benzyl n-[(5s)-5-[[(2r,3s)-3- (formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]- 6-oxo-6-(2-thiazolylamino)hexyl]-carbamate
benzyl n-[(5s)-5-[(2r,3s)-3-(n-hydroxyformamido)-2-(2-methylpropyl)hexanamido]-5-[(1,3-thiazol-2-yl)carbamoyl]pentyl]carbamate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.85 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]